John G. New
50 IP cases indexed. Covers patent matters.
Cases Presided Over
50 cases indexed | Page 2 of 2
Dr. Squatch, LLC v.The Procter & Gamble Company
Dr. Squatch successfully petitioned against Procter & Gamble's deodorant patent, leading the PTAB to institute the case after finding a reasonable likelihood of unpatentability. The Board found multiple grounds of obviousness (35 U.S.C. § 103) across various claims using combinations of prior art references.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical successfully challenged EMKinetics' patent (9002477) in a PTAB decision, asserting that the claims were anticipated or obvious. The Board found strong evidence supporting unpatentability over multiple prior art references, moving the case toward trial.
Avation Medical, Inc. v.EMKinetics, Inc.
The PTAB found that all ten challenged claims of the patent were unpatentable. The decision concluded that the claims were either anticipated by or obvious over various cited prior art references in electrical stimulation therapy.
Penumbra, Inc. v.RapidPulse, Inc.
Penumbra successfully petitioned to institute IPR against RapidPulse regarding claims related to aspiration thrombectomy systems. The Board found a reasonable likelihood of obviousness across multiple grounds, including combinations involving Yang and Mullins.
Solus Advanced Materials Co., Ltd. et al. v.SK nexilis Co., Ltd.
The PTAB denied the IPR petition against claims 1-4 of U.S. Patent No. 9,457,541, finding that the combination of prior art references did not render the copper foil obvious. The Board ruled that the petitioner failed to demonstrate a reasonable expectation of success when combining properties from materially different sources.
Solus Advanced Materials Co., Ltd. et al. v.SK nexilis Co., Ltd.
Solus Advanced Materials Co. lost its request for rehearing after the PTAB denied institution of IPR against SK nexilis regarding copper foil patents.
Solus Advanced Materials Co., Ltd. et al. v.SK nexilis Co., Ltd.
Solus Advanced Materials Co., Ltd.'s request for rehearing was denied by the PTAB, upholding the initial decision to deny institution of IPR against SK nexilis's copper foil patent.
Cala Health, Inc. v.EMKinetics, Inc.
The Board issued an order granting Cala Health and EMKinetics' joint request to keep their Confidential Settlement Agreement private under 37 C.F.R. §42.74(c). The agreement will be treated as business confidential information and kept separate from the patent file.
Cala Health, Inc. v.EMKinetics, Inc.
The PTAB issued an order in IPR2024‑00732 and IPR2024‑00743 requiring Cala Health and EMKinetics to file a true copy of their settlement agreement before the proceedings can be terminated.
Cala Health, Inc. v.EMKinetics, Inc.
The PTAB issued an order granting Cala Health and EMKinetics' joint request to keep their settlement agreement confidential under 37 C.F.R. §42.74(c), separating it from the IPR file.
Cala Health, Inc. v.EMKinetics, Inc.
The PTAB issued an order compelling Cala Health and EMKinetics to file a true copy of their settlement agreement before the joint motion to dismiss can be acted upon, emphasizing compliance with 37 C.F.R. § 42.74(b). A dissenting judge argues the rule does not apply pre‑institution.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health and EMKINETICS settled their dispute over two patents, filing a joint motion that led the PTAB to terminate the inter partes review proceedings before trial.
Cala Health, Inc. v.EMKinetics, Inc.
Cala Health and EMKinetics settled their dispute over two patents, filing a joint motion that led the PTAB to terminate the IPRs before any trial was instituted.
Intersect ENT, Inc. et al. v.New Amsterdam, LLC
Intersect ENT and New Amsterdam settled their IPR dispute over U.S. Patent 6,916,483, filing a joint motion that led the PTAB to terminate the proceeding before trial.
Avation Medical, Inc. v.EMKinetics, Inc.
Avation Medical successfully secured the institution of its IPR against EMKinetics, challenging claims 1-13 based on obviousness over combinations of prior art. The Board found that Petitioner adequately supported unpatentability by demonstrating skilled artisans could make the claimed modifications to existing nerve stimulation methods.
Avation Medical, Inc. v.EMKinetics, Inc.
The PTAB found all 13 challenged claims unpatentable under 35 U.S.C § 103. The Board concluded that the claimed nerve stimulation therapy was obvious over combinations of prior art, specifically citing modifications to Svihra and Amarenco using Mann and Ponsford. This decision confirms the lack of inventive step for the technology described in the patent.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s and Eye Therapies settled their IPR dispute, resulting in a joint motion that terminated the proceedings. The Board granted the termination and kept the settlement confidential.
Formycon AG v.Regeneron Pharmaceuticals, Inc.
Formycon secured an institution of IPR against Regeneron's VEGF‑antagonist formulation patent (10,464,992), covering claims 1‑18, after the Board found a reasonable likelihood of success.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom failed to convince the PTAB that Abbott's glucose monitoring patent was unpatentable based on obviousness grounds. The Board denied institution, finding insufficient evidence across multiple prior art combinations.
Dr. Reddy's Laboratories S.A. et al. v.Eye Therapies, LLC et al.
Dr. Reddy’s Laboratories and Eye Therapies entered a settlement that led to the joint termination of two inter partes review proceedings covering patents 11,833,245 and 11,596,600. The Board granted the termination and kept the settlement agreement confidential.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.